PT-141 & Kisspeptin: What the Science Says About “Pleasure Peptides”
Updated: August 17, 2025 • Educational content only.
Interest in “pleasure peptides” is surging. Two names lead the conversation: PT-141 (bremelanotide), an FDA-approved option for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; and kisspeptin, a neuropeptide under study for modulating sexual desire and arousal.
PT-141 (bremelanotide): the approved option
- Regulatory status: FDA-approved in 2019 as an on-demand, self-administered auto-injector for premenopausal women with HSDD.
- How it works: Acts centrally on melanocortin receptors, distinct from PDE-5 inhibitors.
- Common considerations: Nausea, flushing, and headache are among reported side effects; it’s Rx-only and not for uncontrolled hypertension or certain cardiovascular conditions.
Kisspeptin: promising but investigational
- Mechanism: Activates the HPG axis and brain regions linked to sexual and emotional processing.
- Evidence so far: Early human studies suggest potential in disorders of sexual desire; larger trials are needed to define indications, dosing, and safety.
Bottom line
PT-141 is available today (for eligible patients, via prescription). Kisspeptin remains investigational but scientifically intriguing.
FAQs
Is kisspeptin available?
No—research only at this stage.
Is PT-141 for men?
PT-141 is approved for premenopausal women with HSDD. Any other use is off-label and requires physician guidance.
Sources
Disclaimer
This content is intended for informational and educational purposes only and is not intended to promote or sell any product. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new supplement or research compound. The statements provided have not been evaluated by the FDA or Health Canada and are subject to change as scientific understanding evolves.